Pfizer plans to pull leukemia drug Mylotarg from U.S. market

06/21/2010 | Reuters

Pfizer will voluntarily take Mylotarg off the U.S. market Oct. 15 after the injectable drug failed to show efficacy during a study when given in combination with chemotherapy to patients with acute myeloid leukemia. The decision follows the FDA's recommendation to withdraw the product because of safety concerns and lack of clinical benefit.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD